<DOC>
	<DOCNO>NCT02786043</DOCNO>
	<brief_summary>The main objective evaluate effect Propionyl-L-Carnitine Hydrochloride clinical pharmacokinetic characteristic effect clinical pharmacokinetic characteristic safety healthy Chinese subject provide basis market authorization registration</brief_summary>
	<brief_title>PK Study Evaluate Effect PLC Healthy Chinese Subjects Multiple-doses</brief_title>
	<detailed_description>This single group subject , open-label , self-controlled , 3 period , multi-doses administration trial . 12 Healthy Chinese volunteer satisfy inclusion criterion enrol equal number male female . Each subject go 7-day Run-in period eliminate remain L-carnitine like substance food ensure baseline level endougenous L-Carnitien stable；In period III , first 4 days，all healthy subject take oral Propionyl-L-Carnitine 1g twice daily ; day 5 , healthy subject take oral Propionyl-L-Carnitine 1g fasting .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Sex : Male female proportion . Healthy individual . Age : 19 45 . Similar age . Weight : All subject need weigh ≥50 kg . BMI within 19~24 kg/m2 . Similar weight subjects.； Blood pressure : SBP 90139mmHg，DBP 6089 mmHg； Subjects need understand agree start trial sign informed consent form . Subjects able communicate investigator comply trial protocol . Laboratory investigation : Any item safety evaluation index baseline value consider clinically significant abnormal investigator study ; Hepatitis B surface antigen positive ; Hepatitis C antibody positive ; HIV , Syphilis positive ; During screen 1st day trial drug administration , ECG abnormality show Drug history : Taken drug inhibit induce hepatic metabolism drug 1 month prior trial ; Taken drug within 2 week prior trial ( include prescription drug , nonprescription drug Chinese herbal drug ) ; Past medical history surgical history : Past medical history include structural heart disease , heart failure , myocardial infarction , angina pectoris , unexplained arrhythmia , Torsade de pointes , ventricular tachycardia , Long QT syndrome sign symptom Long QT syndrome family history ( evidence genetic test relative die sudden cardiac death young age ) ; Thyroid disease history receive thyroid surgery ; Immune diseases history ( e.g . thymus disorder history ) ; Received surgery within 6 month prior trial ; Serious gastrointestinal disease history ( e.g . clinically significant gallbladder disease , know suspected jaundice , hepatocellular adenoma , hepatic cavernous hemangioma hepatic disease ) ; Any gastrointestinal , hepatic renal disease affect drug absorption metabolism within 6 month prior trial ( exclude regardless resolve ) ; Any serious cerebrovascular , respiratory , metabolic neurological disease history ; Hematological disease like clot disorder ; Tumor history ; Hypokalemia , hypocalcemia accord low limit reference range provide clinical laboratory ; Lifestyle : Frequent alcohol intake within 6 month prior trial . Over 14 unit alcohol intake per week ( 1 unit = 17.7ml ethanol , 1 unit = 357 ml 5 % alcohol beer 44ml 40 % liquor 147 ml 12 % alcohol wine ) ; Smoke &gt; 1 cigarette per day within 3 month prior trial ; Drug abuse history take drug ( marijuana , cocaine , opiates , benzodiazepine , amphetamine , barbiturate , methadone , tricyclic antidepressant , etc . ) within 1 year prior trial ; Drink excess tea , coffee caffeinecontaining drink ( 8 cup ) per day 2 day drug administration 8 day drug administration ; Drink grapefruit juice 2 day drug administration 8 day drug administration ; Others : Did consent use effective contraceptive method enrollment 3 month drug administration ; Hypersensitivity include know allergy excipients drug ( microcrystalline cellulose , lactose , silica powder , sodium carboxymethyl starch , magnesium stearate ) ; Participated clinical trial within 3 month prior trial planned participate clinical trial 1 month enrollment last drug administration visit ; Blood donation within 3 month prior trial planned donate blood 1 month enrollment last drug administration visit ; Any food allergy special request diet comply unified diet ; Subjects consider excluded investigator ; For female subject , follow criterion meet , apart criterion , also exclude : Taken oral contraceptive pill within 1 month prior trial ; Long term use estrogen progesterone injection implant within 6 month prior trial ; Fertile female subject without use contraceptive method 2 week prior trial ; Fertile female subject spouse consent use follow contraceptive method , condom , intrauterine device , etc . enrollment 3 month drug administration ; During pregnancy lactation ; Urine pregnancy test positive ;</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>